rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Rami Elghandour

Director and Officer

Company insider

Files Form 4 as: Director and Officer, Arcellx; President & CEO, Nevro.

Every Form 4 they filed

In numbers

Trades disclosed
162
Buys
0
Sells
22
Bought
$0
Sold
$39.5M
Companies
2
Companies where not an officer
0
First trade
5 Nov 2014
Last trade
28 Apr 2026
Last filed
28 Apr 2026

Companies traded

Where they are an officer
ArcellxDirector, Officer · Biotechnology · last 28 Apr 20260 buys · 15 sells
NevroDirector, Officer · last 3 Jan 20190 buys · 7 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
40Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
28 Apr 2026filed 28 Apr 2026ArcellxBiotechnologySEC FORM 4 Code U—174,887filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—810,102filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—55,459filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—167,973filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—208,333filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code A—147,745filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—147,745filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code A—284,388filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—284,388filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code A—138,888filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivative · BiotechnologySEC FORM 4 Code D—138,888filing
28 Apr 2026filed 28 Apr 2026ArcellxBiotechnologySEC FORM 4 Code U—198,000filing
28 Apr 2026filed 28 Apr 2026ArcellxBiotechnologySEC FORM 4 Code U—218,500filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—1,068,005filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—837,602filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—120,000filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—245,065filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—255,965filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—810,102filing
28 Apr 2026filed 28 Apr 2026Arcellxoption or derivativeSEC FORM 4 Code D—55,459filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1
Not placed22

Buys in green, sells in red, by the company’s sector.

Related people

Andrew H. GalliganDirector · Director at Arcellx, filing Form 4 there in the last year
David Charles LubnerDirector · Director at Arcellx, filing Form 4 there in the last year
Jill CarrollDirector · Director at Arcellx, filing Form 4 there in the last year
Ali BehbahaniDirector · Director at Arcellx, filing Form 4 there in the last year
Olivia C. WareDirector · Director at Arcellx, filing Form 4 there in the last year